Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease

Brain

Volumn 136, Issue 11, 2013, Pages 3282-3289

  Müller, Martijn L T M ^a   Albin, Roger L ^b,c   Kotagal, Vikas ^b   Koeppe, Robert A ^a   Scott, Peter J H ^a   Frey, Kirk A ^a,b   Bohnen, Nicolaas I ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VAAAHS   (United States)

Author keywords

Acetylcholine; Parkinson's disease; Pedunculopontine nucleus; Positron emission tomography; Postural sensory organization

Indexed keywords

ACETYLCHOLINESTERASE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DOPAMINERGIC INNERVATION; FEMALE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTURAL SENSORY INTEGRATION; PRIORITY JOURNAL; THALAMUS; VIBRATION SENSE;

EID: 84890522859     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt247     Document Type: Article

References (64)

1. Aravamuthan BR, Muthusamy KA, Stein JF, Aziz TZ, Johansen-Berg H. Topography of cortical and subcortical connections of the human pedunculopontine and subthalamic nuclei. Neuroimage 2007; 37: 694-705.
2. Aravamuthan BR, Stein JF, Aziz TZ. The anatomy and localization of the pedunculopontine nucleus determined using probabilistic diffusion tractography [corrected]. Br J Neurosurg 2008; 22: S25-32.
3. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol 1983; 61: 101-8.
4. Ashburn A, Stack E, Ballinger C, Fazakarley L, Fitton C. The circumstances of falls among people with Parkinson's disease and the use of Falls Diaries to facilitate reporting. Disabil Rehabil 2008; 30: 1205-12.
5. Bohnen NI, Albin RL. Cholinergic denervation occurs early in Parkinson disease. Neurology 2009; 73: 256-7.
6. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564-73.
7. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006a; 26: 1198-212.
8. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006b; 253: 242-7.
9. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 315-19.
10. Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009; 73: 1670-6.
11. Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MR, Gilman S, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012; 32: 1609-17.
12. Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 1983; 59: 277-89.
13. Chong RK, Horak FB, Frank J, Kaye J. Sensory organization for balance: specific deficits in Alzheimer's but not in Parkinson's disease. J Gerontol A Biol Sci Med Sci 1999; 54: M122-8.
14. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75: 1263-9.
15. Colnat-Coulbois S, Gauchard GC, Maillard L, Barroche G, Vespignani H, Auque J, et al. Management of postural sensory conflict and dynamic balance control in late-stage Parkinson's disease. Neuroscience 2011; 193: 363-9.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
17. Frenklach A, Louie S, Koop MM, Bronte-Stewart H. Excessive postural sway and the risk of falls at different stages of Parkinson's disease. Mov Disord 2009; 24: 377-85.
18. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 1991; 114: 2253-67.
19. Gallezot JD, Bottlaender M, Gregoire MC, Roumenov D, Deverre JR, Coulon C, et al. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med 2005; 46: 240-7.
20. Gilman S, Koeppe RA, Nan B, Wang CN, Wang X, Junck L, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010; 74: 1416-23.
21. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007; 22: 41-7.
22. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020-8.
23. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-70.
24. Grimaldi G, Manto M. Topography of cerebellar deficits in humans. Cerebellum 2012; 11: 336-51.
25. Hazrati LN, Parent A. Projection from the deep cerebellar nuclei to the pedunculopontine nucleus in the squirrel monkey. Brain Res 1992; 585: 267-71.
26. Heckers S, Geula C, Mesulam MM. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol 1992; 325: 68-82.
27. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 1987; 84: 5976-80.
28. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
29. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
30. Jahn K, Deutschlander A, Stephan T, Strupp M, Wiesmann M, Brandt T. Brain activation patterns during imagined stance and locomotion in functional magnetic resonance imaging. Neuroimage 2004; 22: 1722-31.
31. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 540-3.
32. Jewett DM, Kilbourn MR, Lee LC. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997; 24: 197-9.
33. Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, Belaid H, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 2010; 120: 2745-54.
34. Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA. Predictors of future falls in Parkinson disease. Neurology 2010; 75: 116-24.
35. Latt MD, Lord SR, Morris JG, Fung VS. Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov Disord 2009; 24: 1280-9.
36. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-40.
37. Martinez-Gonzalez C, Bolam JP, Mena-Segovia J. Topographical organization of the pedunculopontine nucleus. Front Neuroanat 2011; 5: 22.
38. Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Virranniemi M, Myllyla VV. Postural sway and falls in Parkinson's disease: a regression approach. Mov Disord 2007; 22: 1927-35.
39. Mattis S. Dementia rating scale. Odessa, FL: Psychological Assessment Resources; 1998.
40. Menant JC, Latt MD, Menz HB, Fung VS, Lord SR. Postural sway approaches center of mass stability limits in Parkinson's disease. Mov Disord 2011; 26: 637-43.
41. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988; 275: 216-40.
42. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238-48.
43. Muller ML, Frey KA, Petrou M, Kotagal V, Koeppe RA, Albin RL, et al. b-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013; 28: 296-301.
44. Nagatsuka S, Fukushi K, Shinotoh H, Namba H, Iyo M, Tanaka N, et al. Kinetic analysis of [11C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab 2001; 21: 1354-66.
45. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-9.
46. Petrou M, Koeppe R, Scott P, Bohnen N, Kilbourn M, Frey K. PET imaging of the vesicular acetylcholine transporter. J Nucl Med 2012; 53 (Suppl 1): Abstract No. 290.
47. Prieto TE, Myklebust JB, Hoffmann RG, Lovett EG, Myklebust BM. Measures of postural steadiness: differences between healthy young and elderly adults. IEEE Trans Biomed Eng 1996; 43: 956-66.
48. Reichert WH, Doolittle J, McDowell FH. Vestibular dysfunction in Parkinson disease. Neurology 1982; 32: 1133-8.
49. Rinne JO, Ma SY, Lee MS, Collan Y, Roytta M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat Disord 2008; 14: 553-7.
50. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3: CD006504.
51. Rossi M, Soto A, Santos S, Sesar A, Labella T. A prospective study of alterations in balance among patients with Parkinson's Disease. Protocol of the postural evaluation. Eur Neurol 2009; 61: 171-6.
52. Shao X, Hoareau R, Runkle AC, Tluczek LJ, Hockley BG, Henderson BD, et al. Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro. J Labelled Comp Radiopharm 2011; 54: 819-38.
53. Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T, et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001; 56: 408-10.
54. Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999; 46: 62-9.
55. Snyder SE, Tluczek L, Jewett DM, Nguyen TB, Kuhl DE, Kilbourn MR. Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998; 25: 751-4.
56. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-53.
57. Villeneuve S, Rodrigues-Brazete J, Joncas S, Postuma RB, Latreille V, Gagnon JF. Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson's disease and REM sleep behavior disorder. Dement Geriatr Cogn Disord 2011; 31: 210-7.
58. Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999; 14: 947-50.
59. Woollacott M, Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 2002; 16: 1-14.
60. Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord 2011; 26: 2496-503.
61. Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012; 78: 545-50.
62. Zesiewicz TA, Sullivan KL. Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14). Clin Neuropharmacol 2008; 31: 363-5.
63. Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL. Treatment of imbalance with varenicline Chantix(R): report of a patient with fragile X tremor/ataxia syndrome. Acta Neurol Scand 2009; 119: 135-8.
64. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989; 26: 41-6.